Annotation of rs1056836

Allele C is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.

SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.

From Publication

Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990). 2014. Lee Soo-Youn et al.
PMID:24361227(opens in new window) DOI:10.1016/j.ejca.2013.11.028(opens in new window)

Gene

CYP1B1

Variant

rs1056836

Phenotype Category

Efficacy, Toxicity

Association Significance

The study reports this association is not significant

PharmGKB ID

1184086220

Score
More info on scoring

-1.25

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    cohort

    Study size

    85

    Association p-value

    > 0.05

    Allele frequency

    C=0.9; G=0.1

    Biogeographical group
    More info on groups

    East Asian

    Population description

    women

    Disease: Metastatic breast cancer (MBC) patients without prior chemotherapy for MBC, detectable brain parenchymal, and/or leptomeningeal metastases, prior gemcitabine therapy, and HER2 + breast cancer with trastuzumab treatment.

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...